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BSTRACT
 
Background
 
The recent recognition that coronary-
artery stenting has improved the short- and long-term
outcomes of patients treated with angioplasty has
made it necessary to reevaluate the relative benefits
of bypass surgery and percutaneous interventions in
patients with multivessel disease.
 
Methods
 
A total of 1205 patients were randomly as-
signed to undergo stent implantation or bypass sur-
gery when a cardiac surgeon and an interventional
cardiologist agreed that the same extent of revascu-
larization could be achieved by either technique. The
primary clinical end point was freedom from major ad-
verse cardiac and cerebrovascular events at one year.
The costs of hospital resources used were also de-
termined.
 
Results
 
At one year, there was no significant dif-
ference between the two groups in terms of the rates
of death, stroke, or myocardial infarction. Among pa-
tients who survived without a stroke or a myocardial
infarction, 16.8 percent of those in the stenting group
underwent a second revascularization, as compared
with 3.5 percent of those in the surgery group. The
rate of event-free survival at one year was 73.8 percent
among the patients who received stents and 87.8 per-
cent among those who underwent bypass surgery
(P<0.001 by the log-rank test). The costs for the ini-
tial procedure were $4,212 less for patients assigned
to stenting than for those assigned to bypass sur-
gery, but this difference was reduced during follow-up
because of the increased need for repeated revascu-
larization; after one year, the net difference in favor
of stenting was estimated to be $2,973 per patient.
 
Conclusions 
 
As measured one year after the pro-
cedure, coronary stenting for multivessel disease is
less expensive than bypass surgery and offers the
same degree of protection against death, stroke, and
myocardial infarction. However, stenting is associated
with a greater need for repeated revascularization.
(N Engl J Med 2001;344:1117-24.)
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HE latest worldwide survey of coronary re-
vascularization shows that 583,000 coro-
nary-artery bypass operations were per-
formed in 1995.
 
1
 
 According to European
statistics, the annual rate of use of balloon angioplas-
ty is approximately 739 procedures per million pop-
ulation.
 
2
 
 Approximately 60 percent of patients treat-
ed with balloon angioplasty or bypass surgery have
multivessel disease that could be treated by either pro-
T
 
cedure.
 
3
 
 The most appropriate treatment remains a
matter of debate. Earlier studies suggested that pa-
tients undergoing either procedure have similar out-
comes in terms of survival and rates of myocardial
infarction, but patients treated with bypass surgery
needed fewer additional interventions.
 
4
 
 However, sub-
sequent improvements in both percutaneous and sur-
gical techniques may now limit the validity of any con-
clusions that have been drawn from the earlier studies.
Reevaluation may be especially important in the
case of angioplasty, since several studies show that cor-
onary stenting necessitates fewer repeated revascu-
larization procedures than does angioplasty without
stenting.
 
5,6
 
 Although surgery may still be considered
more appropriate than conventional balloon angio-
plasty for multivessel disease, this may not be the case
when stent placement is performed in conjunction
with balloon angioplasty.
 
7,8
 
Another reason to reevaluate these surgical and
percutaneous techniques is the growing concern about
the cost of health care. Although stenting may still be
less effective than surgery, as indicated by the need for
repeated revascularization, its use may result in cost
savings.
 
6,9,10
 
 Increasingly, the additional effects of
new therapies must be weighed against their costs.
 
11-13
 
Therefore, the Arterial Revascularization Therapies
Study was designed to compare not only clinical out-
comes, but also the costs to the hospital of resources
associated with bypass surgery and stenting and the
relative cost effectiveness of the procedures.
 
METHODS
 
Study Design
 
We conducted a randomized trial comparing coronary bypass
surgery with percutaneous transluminal coronary angioplasty and
stenting. For each patient, entry into the study required agreement
on the part of a surgeon and an interventional cardiologist that
an equivalent degree of revascularization could be attained by ei-
ther approach. Our analysis incorporates data on the clinical effica-
cy of the procedures, the costs, the cost effectiveness, and the pa-
Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
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tient’s quality of life after 30 days and at 1, 3, and 5 years. An
extensive description of the study’s aims, the selection of patients,
the criteria for exclusion, the procedural guidelines, and the admin-
istrative structure has been published previously.
 
14
 
Selection of Patients
 
Patients who had not previously undergone bypass surgery or
angioplasty were eligible for coronary revascularization if they had
either stable angina pectoris (Canadian Cardiovascular Society class
I, II, III, or IV)
 
15
 
 or unstable angina pectoris (Braunwald class
IB, IC, IIB, IIC, IIIB, or IIIC)
 
16
 
 or if they had silent ischemia
and at least two new lesions that were located in different vessels
and territories (not including the left main coronary artery) and
that were potentially amenable to stent implantation. Patients gave
written informed consent and were randomly assigned to a treat-
ment group over the telephone by the central office of the study.
One major epicardial vessel or side branch with total occlusion
could be included and targeted, provided that the occlusion had
been present for less than one month (according to the clinical
history) and that one other major vessel had clinically significant
stenosis that was amenable to stenting. Conventional balloon an-
gioplasty was permitted, as a complementary treatment without
stent implantation, in vessels between 1.50 mm and 2.75 mm in
diameter if at least two substantial lesions were targeted for stent-
ing. Each patient had to require more than one stent. Decisions
to place stents in lesions at bifurcations, in side branches, or in ves-
sels with fresh thrombi, calcifications, very long obstructions (long-
er than 20 mm), or complex anatomical features were left to the
discretion of the operators.
Patients had to have a left ventricular ejection fraction of more
than 30 percent, and patients with overt congestive heart failure
were excluded.
 
14,17
 
 Patients were also excluded if they had a history
of a cerebrovascular accident; if they had had transmural myocardial
infarction in the previous week; if they had severe hepatic or renal
disease, diseased saphenous veins, neutropenia or thrombocytope-
nia, or an intolerance or contraindication to acetylsalicylic acid or
ticlopidine; or if they needed concomitant major surgery (e.g., valve
surgery, resection of an aortic or left ventricular aneurysm, carot-
id endarterectomy, or surgery for an abdominal aortic aneurysm).
 
End Points
 
The primary end point was freedom, for 12 months after ran-
domization, from major adverse cardiac or cerebrovascular events,
defined as death; stroke, transient ischemic attacks, and reversible
ischemic neurologic deficits
 
14
 
; documented nonfatal myocardial in-
farction; and repeated revascularization by percutaneous interven-
tion or surgery. Deaths from all causes were reported.
In the first seven days after the intervention, a definite diagno-
sis of myocardial infarction was made if there was documentation
of new abnormal Q waves (according to the Minnesota code)
 
18
 
 and
either a ratio of serum creatine kinase MB (CK-MB) isoenzyme to
total cardiac enzyme that was greater than 0.1 or a CK-MB value
that was five times the upper limit of normal. Serum creatine ki-
nase and CK-MB isoenzyme concentrations were measured 6, 12,
and 18 hours after the intervention. Beginning eight days after the
intervention (the length of the hospital stay after surgery), either ab-
normal Q waves or enzymatic changes were sufficient for a diagno-
sis of myocardial infarction. This two-part method of defining my-
ocardial infarction was used to eliminate the difficulty of diagnosing
a myocardial infarction after surgery.
 
19,20 
 
A myocardial infarction was
confirmed only after the relevant electrocardiograms had been an-
alyzed by the electrocardiographic core laboratory and adjudicated
by a clinical-events committee. All revascularization procedures af-
ter the initial intervention and the reasons for them were recorded.
The secondary objective of this study was to compare the two
treatment strategies at one year with respect to the following: an-
gina status, use of medications, costs, cost effectiveness, and quality
of life; a combined end point of death, myocardial infarction, or
stroke; and the rates of death, myocardial infarction, stroke, and re-
vascularization procedures. Events were counted from the time
of randomization, whereas clinical status was assessed 1 month,
6 months, and 12 months after a planned intervention.
 
Costs, Efficacy, and Cost Effectiveness
 
The costs that were considered were the direct medical costs to
the hospital per patient, calculated as the number of resource units
(therapeutic procedure, diagnostic procedure, or device) used mul-
tiplied by the cost per unit. The resources included outpatient visits,
hospital days, postoperative intensive care, coronary care, noninten-
sive and noncoronary care, diagnostic tests (e.g., clinical laboratory
tests), therapeutic procedures measured in terms of their duration
(e.g., angiography and surgery), materials consumed (e.g., bal-
loons, wires, catheters, and stents used in revascularization), med-
ication, and rehabilitation services. Patients were also given a “pass-
port” so that the same data could be recorded if they were treated
at other hospitals. Unit costs were estimated before the data were
analyzed and the estimates were based on detailed information pro-
vided by the Dijkzigt Hospital, Rotterdam, the Netherlands, as
reported previously.
 
6,10
 
*Plus–minus values are means ±SD.
†The body-mass index is defined as the weight in kilograms divided by
the square of the height in meters.
‡Stable angina was defined according to the system of the Canadian Car-
diovascular Society.
 
15
 
§Unstable angina was defined according to the system of Braunwald.
 
16
 
¶The vessel territory and the extent of occlusion involved were assessed
by an independent angiographic core laboratory.
¿Involvement of a left main coronary artery was a violation of the study
protocol.
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(N=605)
 
Male sex (% of patients) 77 76
Age (yr)
Mean
Range
61±10
30–83
61±9
32–82
Body-mass index† 27.2±3.7 27.4±3.7
Previous conditions (% of patients)
Q-wave or non–Q-wave myocardial infarction 44 42
Diabetes mellitus 19 16
Hypertension 45 45
Hypercholesterolemia 58 58
Family history of myocardial infarction 39 42
Peripheral vascular disease 6 5
Chronic obstructive pulmonary disease 5 5
Current smoker (% of patients) 28 26
Stable angina (% of patients)‡ 57 60
Unstable angina (% of patients)§ 37 35
Silent ischemia (% of patients) 6 5
Ejection fraction (%) 61±12 60±13
No. of segments with stenosis >50% of luminal
diameter
2.83±1.02 2.80±1.04
Number of diseased vessels (% of patients)
1 2 0
2 68 67
3 30 33
Vessel territory with stenosis (% of patients)¶
Right coronary artery 71 72
Left anterior descending artery 90 90
Left circumflex artery 71 72
Left main coronary artery¿ 0 0
Bifurcation or side branch involved (% of patients)¶ 34 31
Total occlusion (% of patients)¶ 3 5
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Efficacy was expressed in terms of the primary end point of
event-free survival. The balance between costs and efficacy was ex-
pressed in terms of the incremental cost-effectiveness ratio, defined
as the additional costs per additional year of survival without a ma-
jor adverse cardiac or cerebrovascular event. Secondary measures
of efficacy were assessed by means of the EuroQol questionnaire
regarding the quality of life, on which patients grade their general
health status.
 
21
 
 The questionnaire comprises five items — mobility,
self-care, usual activity, pain or discomfort, and anxiety or depres-
sion — each of which may be rated as “no problem,” “moderate
problem,” or “severe problem.” These ratings were then summa-
rized (EuroQol summary) after being weighted to account for dif-
ferences in the importance of the various items to the patient.
 
21
 
 The
questionnaire also includes a visual-analogue scale (EuroQol ther-
mometer) for patients to use in rating their overall status from
0 (“worst” imaginable health) to 100 (“best” imaginable health).
 
Statistical Analysis
 
A total of 600 patients in each of the two groups was required
for the study to be able to reject the null hypothesis that at one year
the difference in the frequency of major adverse cardiac and cere-
brovascular events (event-free survival) in favor of bypass surgery
would not exceed 7 percentage points. With the actual sample size,
the study achieved a power of 92 percent with the assumption of
a two-sided type I error level (
 
a
 
) of 0.05.
Continuous variables were estimated as means ±SD and com-
pared with use of Student’s unpaired t-test. Fisher’s exact test was
used for categorical variables with nominal scales and the Wilcox-
on or Mann–Whitney rank-sum test for those with ordinal scales.
Discrete variables were reported as counts and percentages and were
compared in terms of relative risks (for the surgery group versus
the stenting group) with 95 percent confidence intervals, calculat-
ed according to the formula of Greenland and Robins.
 
22
 
 All analy-
ses were based on the intention-to-treat principle, and statistical
tests were two-tailed.
Event-free survival was estimated by the Kaplan–Meier method,
and differences were assessed by means of the log-rank test. A mul-
tivariate logistic-regression model was created with the use of base-
line clinical and angiographic characteristics and procedure-related
variables (including the method of revascularization — i.e., stent-
ing or surgery) in order to identify independent predictors of the
primary end point (event-free survival at one year).
Expectations about costs and cost effectiveness have been report-
ed previously.
 
14
 
 In that report, incremental cost-effectiveness ratios
were expressed with the use of Fieller’s approximation (with 95 per-
cent confidence intervals).
 
23
 
RESULTS
 
Characteristics and Treatment of the Patients
 
Between April 1997 and June 1998, 1205 patients
at 67 participating centers were randomly assigned to
undergo stent implantation (600 patients) or bypass
surgery (605 patients). Table 1 presents their base-line
demographic and angiographic characteristics. Five pa-
tients, one assigned to stenting and four assigned to
surgery, did not undergo coronary revascularization
and instead continued to receive pharmacologic treat-
ment. The average interval between randomization
and treatment was 27±39 days (range, 0 to 362) for
 
*One patient in the stenting group had a myocardial infarction while on the waiting list for the
procedure; in the surgery group, three patients died while on the waiting list, one patient had a cere-
brovascular accident, and four patients had myocardial infarctions. CI denotes confidence interval,
CABG coronary-artery bypass grafting, and PTCA percutaneous transluminal coronary angioplasty.
†If a patient required repeated angioplasty and later required coronary-artery bypass grafting, only
the worst event (CABG) was counted as an event.
‡If a patient required repeated angioplasty and later required coronary-artery bypass grafting, the
total count for “CABG” and “PTCA” at 365 days would reflect both events, not just the worst that
occurred, but the count for the general variable “Repeated revascularization” would reflect only one
event.
§In the stenting group, five cerebrovascular accidents were thrombotic, one was hemorrhagic, and
the nature of the other four is unknown. In the surgery group, seven were thrombotic, one was hem-
orrhagic, and the nature of the other five is unknown.
¶P<0.001 by the Wilcoxon rank-sum test.
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(95% CI)
 
STENTING
GROUP
 
(
 
N
 
=600)
 
SURGERY
GROUP
 
(
 
N
 
=605)
 
STENTING
GROUP
 
(
 
N
 
=600)
 
SURGERY
GROUP
 
(
 
N
 
=605)
 
number (percent)
 
Death 15 (2.5) 17 (2.8) 15 (2.5) 17 (2.8) 0.89 (0.45–1.77)
Cerebrovascular accident§ 9 (1.5) 12 (2.0) 10 (1.7) 13 (2.1) 0.78 (0.34–1.76)
Myocardial infarction 32 (5.3) 24 (4.0) 37 (6.2) 29 (4.8) 1.29 (0.80–2.06)
Q-wave 28 (4.7) 22 (3.6) 32 (5.3) 26 (4.3) 1.24 (0.75–2.06)
Non–Q-wave 4 (0.7) 2 (0.3) 5 (0.8) 3 (0.5) 1.68 (0.40–7.00)
Repeated revascularization 101 (16.8) 21 (3.5) 126 (21.0) 23 (3.8) 5.52 (3.59–8.49)
CABG 28 (4.7) 3 (0.5) 40 (6.7) 4 (0.7) 10.08 (3.63–28.01)
PTCA 73 (12.2) 18 (3.0) 94 (15.7) 20 (3.3) 4.74 (2.96–7.58)
Event-free survival¶ 443 (73.8) 531 (87.8) — — —
Any event 157 (26.2) 74 (12.2) — — 2.14 (1.66–2.75)
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patients in the surgery group and 11±16 days (range,
0 to 173) for patients in the stenting group. Three
patients died while waiting for surgery. Six patients
randomly assigned to stent implantation were instead
treated surgically, and 19 patients randomly assigned
to bypass surgery were instead treated with stent
implantation. During the initial hospital stay, after
complicated or unsatisfactory angioplasty procedures,
14 patients assigned to stent implantation under-
went bypass surgery, 3 urgently and 11 electively.
Conversely, two patients in the surgical group un-
derwent angioplasty during their hospital stay. A
total of 99 percent of the patients in the stenting
group (593 patients) and 96 percent of those in the
surgery group (579 patients) received the assigned
treatment.
Assessment of Revascularization and Postprocedural 
Enzyme Levels
Among the patients in the stenting group, a mean
(±SD) of 2.8±1.0 lesions with stenosis of more than
50 percent of the luminal diameter were detected on
the diagnostic angiogram, and 2.6±1.1 lesions had
stents placed (89 percent) or were treated with balloon
angioplasty alone (11 percent). However, in 15.2 per-
cent of the patients in the stenting group, one or
more of the target lesions did not receive the intended
treatment, whereas in 10.2 percent of these patients
procedures were performed that were not initially
planned. In the surgery group, a mean of 2.8±1.0 le-
sions were found per patient, and a mean of 2.6±1.0
anastomoses were performed with the use of a mean
of 2.5±0.7 conduits. In 4.5 percent of patients in
this group, however, the intended surgical procedure
was not performed. In 93 percent of the patients in
the surgery group, at least one arterial conduit was
used; in 95 percent of these patients, the left anterior
descending artery was revascularized with an arterial
conduit. In the stenting group, the average total length
of the stents implanted was 47.5±21.8 mm per pa-
tient; 27 percent of the individual stents were longer
than 15 mm. Bypass surgery required an average of
234±74 minutes, whereas stenting took an average
of 98±52 minutes (P<0.001).
In the first 18 hours after the intervention, abnor-
mal CK-MB levels were observed in 61 percent of the
patients in the surgery group and 31 percent of the
patients in the stenting group. Creatine kinase values
more than five times the upper limit of normal were
found in 12.6 percent of the patients in the surgery
group and 6.2 percent of the patients in the stenting
group (P<0.001).
Clinical Outcomes
In the stenting group, 40 percent of the major ad-
verse events that occurred in the first 30 days after
intervention were due to stent thrombosis. This com-
plication occurred in 1.1 percent of the stented le-
Figure 1. Actuarial Survival (Panel A), Kaplan–Meier Estimates
of Survival without Myocardial Infarction or Cerebrovascular
Events (Panel B), and Kaplan–Meier Estimates of Survival with-
out Cerebrovascular Events, Myocardial Infarction, or Repeated
Revascularization (Panel C) among Patients Assigned to Under-
go Stenting, as Compared with Those Assigned to Undergo
Coronary-Artery Bypass Grafting (CABG).
There was a significant difference between the groups in sur-
vival without cerebrovascular events, myocardial infarction, or
repeated revascularization (P<0.001 by the log-rank test).
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showed that an elevated level of CK-MB was the main
predictor of outcome in the surgery group, whereas
the presence of diabetes mellitus was the key predic-
tor of outcome in the stenting group.
Quality of Life
Throughout the 12-month period of observation,
more patients were free of angina after bypass sur-
gery than after stenting (Table 3). The data from the
self-rated EuroQol questionnaire indicated a signifi-
cantly better quality of life with stenting after 1 month,
no difference after 6 months, and a slight difference
in favor of surgery after 12 months. The difference
at 12 months was attributable to significant differ-
ences in the ratings for “usual activity” and “anxiety
or depression” and a nonsignificant difference in rat-
ings for “mobility.”
Costs and Cost Effectiveness
As Table 4 shows, the total costs of bypass surgery
($10,653) were significantly greater than those of
stenting ($6,441). The difference was due primarily
to the differences in the duration of the procedures
and the length of the hospital stay. The initial differ-
ence of $4,212 was later reduced because patients in
the stenting group required more repeated revascu-
larizations. Thus, the net difference in favor of stent-
ing had decreased to $2,973 by one year. Had a pol-
icy of performing elective bypass surgery rather than
angioplasty and stenting been applied to every pa-
tient enrolled in the trial, the additional costs at one
year would have been approximately $21,329 per ad-
ditional patient who survived event-free.
sions but in 2.8 percent of the patients. The frequen-
cy of major adverse cardiac and cerebrovascular events
and the number of patients in whom each type of
event occurred are shown in Table 2. One of these
events occurred in 157 of the 600 patients assigned
to stent implantation (26.2 percent), as compared
with 74 of the 605 patients assigned to bypass sur-
gery (12.2 percent; relative risk, 2.14; 95 percent
confidence interval, 1.66 to 2.75). Similar numbers
of patients in the two groups were alive at one year
and had not had a stroke or a myocardial infarction
(90.7 percent in the stenting group and 91.2 percent
in the surgery group; relative risk of death, stroke,
or nonfatal myocardial infarction, 1.07; 95 percent
confidence interval, 0.75 to 1.52). Of these patients,
16.8 percent in the stenting group and 3.5 percent
in the surgery group underwent repeated revascular-
ization (an absolute difference of 13.3 percent). Over-
all, 21.0 percent of the patients in the stenting group
underwent additional revascularization, as compared
with 3.8 percent of those in the surgery group (rel-
ative risk, 5.52; 95 percent confidence interval, 3.59
to 8.49). The different clinical outcomes are illustrat-
ed by the Kaplan–Meier estimates of event-free sur-
vival in the two original groups and among patients
who survived for one year without a stroke or a my-
ocardial infarction (Fig. 1). The better outcome at one
year for the patients in the surgery group was also
reflected in a significantly higher proportion of pa-
tients without angina (90 percent after bypass surgery
vs. 79 percent after stenting) and a lower rate of use
of antianginal medications (Table 3).
Multivariate Cox regression analysis in this trial
*Plus–minus values are means ±SD. High scores on the EuroQol thermometer and the EuroQol summary indicate a good quality of life, whereas low
scores on the other five items — mobility, self-care, usual activity, pain or discomfort, and anxiety or depression — reflect a favorable assessment of each
individual component of the quality of life.
†Respondents rate their overall health status using a 20-cm visual-analogue scale. This scale, which is similar to a thermometer, is marked 100 at the top
(best imaginable state of health) and 0 at the bottom (worst imaginable state of health).
‡Information elicited on the five EuroQol domains is converted into a single EuroQol summary (range, 0 to 100) after the individual scores have been
weighted to account for differences in the importance of the various domains to the patient.
TABLE 3. STATUS WITH RESPECT TO ANGINA AND MEDICATION USE AND QUALITY OF LIFE AMONG SURVIVING PATIENTS.*
VARIABLE BASE LINE 1 MO AFTER INTERVENTION 6 MO AFTER INTERVENTION 12 MO AFTER INTERVENTION
STENTING
GROUP
SURGERY
GROUP
STENTING
GROUP
SURGERY
GROUP
P
VALUE
STENTING
GROUP
SURGERY
GROUP
P
VALUE
STENTING
GROUP
SURGERY
GROUP
P
VALUE
Free of angina (%) 0 0 87.2 95.5 <0.001 75.5 92.7 <0.001 78.9 89.5 <0.001
Free of antianginal medication (%) 7.5 4.6 16.4 29.4 <0.001 18.6 39.0 <0.001 21.1 41.5 <0.001
Free of angina and antianginal
medication (%)
0 0 14.9 28.6 <0.001 14.6 36.3 <0.001 19.1 38.4 <0.001
EuroQol thermometer† 58±19 59±18 75±16 71±16 <0.001 78±15 78±15 0.62 78±15 80±15 0.11
EuroQol summary‡ 69±20 68±20 84±16 78±17 <0.001 86±16 86±15 0.46 86±16 87±16 0.24
EuroQol domain
Mobility 4.1±6.0 4.0±5.9 1.5±3.3 1.5±3.3 0.94 1.4±3.3 1.1±2.5 0.06 1.4±2.8 1.1±2.8 0.05
Self-care 1.6±4.1 1.5±3.9 0.4±1.9 1.1±3.4 <0.001 0.4±1.9 0.2±1.6 0.10 0.4±2.1 0.4±2.5 0.53
Usual activity 2.9±3.0 2.9±3.0 1.3±2.2 2.5±2.7 <0.001 1.0±1.8 0.8±1.8 0.12 1.0±1.9 0.8±1.8 0.01
Pain or discomfort 10.9±9.2 11.1±9.5 4.7±6.8 8.0±7.3 <0.001 4.8±7.2 5.1±6.8 0.28 4.4±7.1 4.6±7.4 0.82
Anxiety or depression 4.8±6.0 5.2±6.8 3.0±4.8 2.7±5.1 0.10 2.5±4.3 2.3±4.1 0.45 2.5±4.5 2.0±4.1 0.04
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DISCUSSION
We found no significant difference between the
two treatment groups in the combined rate of death,
stroke, and myocardial infarction; a difference of 17.2
percentage points in the rate of repeated revasculariza-
tion in favor of surgery; and lower costs (by $2,973)
at 12 months in favor of coronary stenting. Our re-
sults present physicians with a dilemma. Angioplasty
with stenting is less invasive than surgery and is as-
sociated with a faster recovery and a better quality
of life one month after the intervention. Bypass sur-
gery is associated with a lower incidence of angina,
less need for antianginal medications, and fewer re-
peated interventions in the first year after the proce-
dure. A decision to perform bypass surgery will prob-
ably cost approximately $3,000 more than a decision
to perform angioplasty with stenting, but it may re-
sult in 14 additional patients with event-free survival
per 100 treated patients, as suggested by the differ-
ence of 14 percentage points in event-free survival in
our study. As compared with stenting, in other words,
it would be necessary to perform bypass surgery in sev-
en patients in order for one additional patient to sur-
vive for one year without adverse events (1.0÷0.14=
7.14); doing so would cost approximately $21,000
— an incremental cost-effectiveness ratio of $21,000
per additional patient who survives event-free. These
figures are substantially more favorable than the cost-
effectiveness estimates for the use of abciximab in pa-
tients who are undergoing angioplasty24 or for the use
of primary balloon angioplasty in patients who have
had a myocardial infarction.25
The interval between randomization and treatment
was approximately three times longer for the patients
in the surgery group than for those in the stenting
group, and eight major adverse cardiac events occurred
in patients assigned to bypass surgery before they had
undergone surgery, as compared with one such event
*The costs per unit have been rounded in the calculation of the average. CCU denotes coronary
care unit, ICU intensive care unit, PTCA percutaneous transluminal coronary angioplasty, and CABG
coronary-artery bypass grafting.
†P values were calculated with use of the Mann–Whitney rank-sum test.
‡Intraoperative hardware includes guiding catheters, guide wires, balloons, stents, atherectomy de-
vices and laser catheters, Doppler and intravascular catheters, cardiopulmonary support and intra-aor-
tic balloon-pump catheters, and endarterectomy devices. Abciximab, as an adjunctive intraoperative
drug, was administered to 18 patients in the stenting group.
§The costs for either a target or a nontarget vessel are included.
TABLE 4. AVERAGE RESOURCE USE PER PATIENT, EFFECTIVENESS, COSTS, 
AND COST EFFECTIVENESS AT ONE YEAR.*
RESOURCE AVERAGE RESOURCE USE COSTS ($)
P 
VALUE†
SURGERY
GROUP
(N=600)
STENTING
GROUP
(N=605)
COSTS 
PER UNIT 
($)
SURGERY 
GROUP
(N=600)
STENTING
GROUP
(N=605)
Procedure
Catheterization laboratory (min) 2.56 97.79 16 42 1,581 <0.001
Operating room (min) 234.41 1.94 27 6,330 54 <0.001
Intraoperative hardware‡ — — — 250 3,471 <0.001
CCU (days) 0.45 0.66 856 386 564 <0.001
ICU (days) 1.89 0.13 941 1,781 118 <0.001
Non-CCU, non-ICU hospitalization 
(days)
6.11 2.14 305 1,864 653 <0.001
Total procedure-related charges 10,653 6,441 <0.001
One-year follow-up
PTCA§ 0.03 0.19 3053 107 579 <0.001
CABG§ 0.01 0.07 6622 44 441 <0.001
Transfusion 0.02 0.02 53 1 1 0.28
Vascular surgery 0.00 0.01 3861 6 19 0.31
Thrombolysis 0.00 0.03 1134 4 32 0.002
Angiography 0.08 0.21 1934 147 396 0.001
Computed tomographic scanning 0.02 0.02 142 3 2 0.84
Other procedure-related resources 0.07 0.02 2265 174 10 <0.001
CCU (days) 0.33 0.61 856 285 525 <0.001
ICU (days) 0.33 0.15 941 314 144 0.07
Non-CCU, non-ICU hospitalization 
(days)
2.50 3.30 305 762 1,005 <0.001
Rehabilitation services (days) 3.42 1.00 145 496 145 <0.001
Medication — — — 642 925 <0.001
Total direct medical costs at 1 yr 13,638 10,665 <0.001
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in a patient assigned to stent implantation. These de-
lays and events handicapped the late follow-up of the
patients in the surgery group. There are reports that
delays caused by waiting lists for cardiac surgery may
pose risks.26-28
The trial was initiated in April 1997, and one-year
follow-up data were available in August 1999. Since
practice evolves continuously, it is relevant to con-
sider the differences between the techniques used in
this study and newly developed techniques for cor-
onary revascularization that may affect future prac-
tice, such as surgery without cardiopulmonary bypass
and new, minimally invasive approaches.29-34 Converse-
ly, the 2.8 percent stent thrombosis rate per patient
might have been prevented by platelet glycoprotein
IIb/IIIa receptor blockade35 or use of a heparin-coat-
ed stent.6,36,37 Furthermore, in 30 percent of the pa-
tients with stents, some release of CK-MB was doc-
umented; the use of glycoprotein IIb/IIIa inhibitors
might have reduced this rate of enzyme release by 50
percent.
The observation that CK-MB enzyme release was
the major predictor of clinical outcome in the surgery
group, whereas the presence of diabetes mellitus was
the key predictor in the stenting group, will further
fuel the debate regarding the prognostic and patho-
physiological significance of cardiac-enzyme release
during surgical revascularization, but it corroborates
the findings of the Bypass Angioplasty Revasculariza-
tion Investigation with respect to the adverse clinical
effects of diabetes in patients treated by percutane-
ous intervention.38
Although surgery remains the most effective meth-
od of revascularization for multivessel disease, our
findings tip the scales of cost effectiveness in favor
of the percutaneous approach by demonstrating a
substantial reduction in the difference between the
outcomes of the procedures. However, “cost” must be
defined from the perspective of society as a whole,
and each patient’s preference must be considered in
making individual decisions. Although the percuta-
neous approach offers the same degree of protection
against death and cardiac or cerebrovascular events
as surgery and is generally perceived by patients as
less invasive, the possible need for further revascular-
ization after an initial percutaneous treatment has to
be weighed by the patient and his or her physician
in choosing an approach.
Supported by Cordis, a Johnson & Johnson company.
We are indebted to Dr. Brian Firth, Paul Marshall, and Dr. Rob-
ert Pigache for their careful review of the manuscript and for their
constructive comments.
APPENDIX
This study was conducted under the auspices of the European Academy
of Sciences and Arts. Patron: Jacques Santer, former president, European
Commission in Brussels. Safety and data monitoring committee: S. Pocock,
T. Ryan, K. Taylor; board of governors: M. Woodall, B. Firth, F. Unger, P.W.
Serruys, P.G. Hugenholtz; executive steering committee: P.W. Serruys (chair),
F. Unger (cochair), L. van Herwerden, F. Mohr, J. Cremer, G. Petterson,
R. Simon, W. Wijns, H. Bonnier, A. Colombo, M.-C. Morice, O. Madon-
na, G.-A. van Es; critical-events committee: J.J. Bredee, O. Hess, W. Mor-
shuis, W. Wijns; angiographic committee: M. van den Brand, B. Rensing, C.
van de Wiel; cardialysis data coordinating center and electrocardiography core
laboratory (Rotterdam): H. Hennessey, A.-M. Hoogenboom, M. Kuypers.
M.-A. Morel, V. de Valk, W. Lindeboom; clinical data monitoring: I. Kuit
(Parexel); health economics analysis: B. van Hout.
The following investigators participated in the study (the numbers in pa-
rentheses indicate the number of patients enrolled by each team): Brazil:
J.E. Sousa, A. Jatene (66); E. Ribeiro, E. Buffolo (26); the Netherlands:
H.J.R.M. Bonnier, J.P.A.M. Schönberger (61); P.W. Serruys, L. van Her-
werden (47); P.C.H. Roose, T.R. van Geldorp (39); H. Suryapranata, M.
Haalebos (27); F. Kiemeney, L. Eysmann (17); F.W.H.M. Bär, K. Prenger
(15); A.J. van Boven, P.W. Boonstra (14); H. Gehlmann, S. Singh (7); K.
Koch, B.A.J. de Mol (2); United Kingdom: N. Buller, R. Bonser (54); M.T.
Rothman, R. Balcon, J. Wright (26); C. Ilsley, M. Yacoub (19); D. Cum-
berland, F. Ciulli, G. Cooper (16); K. Dawkins, S. Livesey (16); Belgium:
V. Legrand, R. Limet (47); W. Wijns, F. Wellens (26); P. van den Heuvel,
C. van Cauwelaert (21); M. Vrolix, G. Fransen (17); P. Materne, G. de Kos-
ter (17); Y. Taeymans, G. van Nooten (16); E. Schroeder, J.C. Schoe-
vaerdts (9); C. Hanet, R. Dion (5); M. Vandormael, P. Bettendorf (4);
Canada: R. Carere, S. Lichtenstein (46); I. Penn, G.F.O. Tyers (20); L.
Bilodeau, M. Carrier (17); Germany: G. Schuler, F.W. Mohr (43); R. Si-
mon, D. Regensburger (25); W. Rutsch, W. Konertz (11); P. Hanrath, B.
Messmer (10); B. Lösse, M.J. Polonius (7); D.C. Gulba, B. Schübel (4);
R. Erbel, M. Haude, J.C. Reidemeister (3); S. Nikol, B. Reichart (2); A.
Schömig, H. Meisner, K. Holper (1); Spain: C. Macaya, J.L. Castañon
(32); F. Fernandez-Avilès, J. Herreros Gonzáles (28); A. Betriu, J.L. Pomar
(14); Austria: G. Heyer, F. Unger (30); P. Probst, E. Wolner, G. Laufer
(11); Israel: R. Beyar, S. Milo (25); C. Lotan, G. Merin (10); S. Braun, R.
Mor (10); D. Tzivoni, D. Bitran (8); Ireland: P. Crean, E. McGovern (22);
Denmark: T. Toftegaard Nielsen, P. Kildeberg Paulsen (18); K. Saunamäki,
K. Sander-Jensen (13); Portugal: R. Seabra-Gomes, J. Queiróz E Melo
(17); V. Gama Ribeiro, M.D.M.S. Guerreiro (13); Argentina: H.F. Londe-
ro, V. Caramutti (16); J. Belardi, D. Navia (3); Switzerland: M. Pieper, D.
Maass (16); J.J. Goy, L.K. von Segesser (7); T. Lüscher, M. Turina (6);
Australia: G.I.C. Nelson, D. Marshman (15); J.H.N. Bett, P. Tesar (11);
Greece: V. Voudris, G. Stavridis (13); France: J.L. Dubois-Rande, D. Lois-
ance (11); M.C. Morice, P. Donzeau-Gouge (9); Italy: G. Binaghi, G.
Tarelli (11); G. Piovaccari, C. Marrozzini, G. Marinelli (10); A. Salvi, L.
Dreas, B. Branchini (8); A. Colombo, C. Santoli (6); I. Sheiban, O. Alfieri
(6); New Zealand: J. Ormiston, P. Ruygrok, A. Kerr (3).
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